May 05, 2025 — ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, is pleased to announce that GenomeFrontier Therapeutics has been awarded a $100,000 G-Rex® Grant to support exploratory studies aimed at enhancing the manufacturing of GF-CART01, GenomeFrontier’s first-in-class, non-viral autologous CAR T cell therapy, which is currently under evaluation for treatment of B cell malignancies in a Phase 1 clinical trial (NCT06703892).
G-Rex® technology is incorporated into the qCART™-based manufacturing process for GF-CART01. qCART™ is a proprietary flexible non-viral platform for the development and manufacture of multiplex CAR T cells that supports integration of large gene payloads, including multiple CARs, modulatory elements and/or safety switches. The process yields high-quality CAR T cell products, which feature enriched T stem cell memory (T-SCM) populations, balanced CD4/CD8 ratios, and minimal exhaustion and senescence gene expression. This platform for adaptable non-viral delivery of complex gene payloads with precise control of T cell function is especially well-suited for generating therapies for solid tumors.
“We are excited to see our G-Rex technology utilized by GenomeFrontier to produce cutting-edge, multiplex CAR T cells with promise for treatment of devastating cancers, including solid tumors,” said John Wilson, founder and CEO of Wilson Wolf. “We are eager to assist GenomeFrontier quickly establish a highly cost-effective manufacturing process that can easily scale all the way to commercial applications.”
“We highly value the G-Rex product, as it is critical to the manufacture of our GF-CART01 therapy,” said Dr. Sareina Wu, Founder and CEO of GenomeFrontier. “We’re also grateful to ScaleReady for supporting continued enhancements to deliver long-term value to patients.”
G-Rex technology plays a key role in the manufacture of GF-CART01, enabling robust and scalable cell expansion under semi-closed conditions. The grant will facilitate improvements that include the transition toward a fully closed, automated manufacturing process, further enhancing the clinical potential and manufacturing scalability of GF-CART01.
In addition to GF-CART01 for B cell malignancies, GenomeFrontier’s pipeline includes GF-CART02 for multiple myeloma and GF-CART03, a multi-modular, armored CAR T therapy targeting a wide-range of hard-to-treat solid tumors. This award will help GenomeFrontier to create a robust and adaptable manufacturing process that can be utilized in the development of safe, effective, and accessible virus-free multiplex CAR/TCR T cell therapies for patients with critical unmet medical needs.
About Wilson Wolf
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex® technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.
Wilson Wolf’s mission is to create hope for cancer patients, one G-Rex® device at a time.
About ScaleReady
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trial sponsors as well as 5 commercially approved CGT drugs.
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About GenomeFrontier
GenomeFrontier is an innovation-driven company that seeks to create a disease-free world by creating effective, affordable and accessible treatments for unmet medical needs. This goal is accomplished by utilizing Quantum Engine™ technology, which integrates four proprietary platforms: Quantum Nufect™, Quantum pBac™, iCellar™, and G-Tailor™. These platforms respectively improve vector delivery, therapeutic gene integration, cell expansion capacity, and gene design. The company is committed to developing state-of-the-art products and platforms for production of next-generation gene-modified cell therapies that are highly effective, specific, persistent, and safe.
For more information about GenomeFrontier, please email contact@genomefrontier.com.